Shares of Neurocrine Biosciences Inc. (NASDAQ:NBIX) spiked more than 25 percent early Wednesday, coming within $2 of their 52-week high, after the FDA approved, on its PDUFA date, the selective vesicular monoamine transporter 2 (VMAT2) inhibitor, Ingrezza (valbenazine), to treat adults with tardive dyskinesia (TD).